Agilent Technologies, Inc.

A · NYSE · USD

Financials

Annual

StatisticsIncome statementBalance sheetCash flowDividendsSegments

Valuation and market statistics · USD millions unless noted · ratios on the twelve months ending at each period

Line item	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008	FY2007	FY2006	FY2005	FY2004	FY2003	FY2002	FY2001	FY2000	FY1999	FY1998
Valuation
Market cap	$41,493	$37,442	$30,245	$40,957	$47,562	$30,831	$22,877	$19,567	$20,545	$13,158	$11,404	$13,163	$12,378	$8,958	$9,199	$8,623	$6,121	$5,761	$10,382	$10,340	$10,656	$8,042	$7,942	$4,306	$6,870	$14,009	$10,944	$12,761
Enterprise value	$43,058	$39,687	$31,390	$42,673	$48,716	$31,749	$23,902	$19,123	$19,882	$12,776	$11,059	$12,611	$12,405	$8,961	$7,865	$9,673	$6,541	$6,457	$10,643	$9,589	$8,405	$6,877	$7,485	$3,612	$5,706	$13,123	–	–
P/E (TTM) at period end	31.84×	29.05×	24.39×	32.66×	39.31×	42.88×	21.36×	61.92×	30.04×	28.48×	28.44×	23.98×	16.86×	7.77×	9.09×	12.61×	–	8.31×	16.27×	3.13×	75.57×	21.79×	–	–	40.89×	18.51×	21.38×	49.66×
P/S (TTM) at period end	5.97×	5.75×	4.43×	5.98×	7.53×	5.77×	4.43×	3.98×	4.59×	3.13×	2.82×	3.25×	3.18×	1.31×	1.39×	1.58×	1.37×	1.00×	1.92×	2.08×	2.07×	1.12×	1.78×	0.72×	0.82×	1.50×	1.60×	1.60×
P/B at period end	6.16×	6.35×	5.17×	7.72×	8.83×	6.33×	4.82×	4.28×	4.25×	3.10×	2.74×	2.48×	2.34×	1.73×	2.14×	2.67×	2.44×	2.25×	3.21×	2.83×	2.61×	2.25×	2.81×	0.93×	1.21×	2.66×	3.24×	4.22×
EV / EBITDA (TTM)	24.37×	22.74×	19.36×	22.05×	29.21×	27.51×	20.27×	17.17×	19.51×	14.84×	14.27×	15.71×	16.37×	6.31×	5.94×	12.59×	31.30×	6.48×	13.73×	15.12×	23.28×	11.50×	–	–	–	9.48×	–	–
EV / Sales (TTM)	6.20×	6.10×	4.59×	6.23×	7.71×	5.95×	4.63×	3.89×	4.45×	3.04×	2.74×	3.12×	3.19×	1.31×	1.19×	1.78×	1.46×	1.12×	1.96×	1.93×	1.64×	0.96×	1.68×	0.60×	0.68×	1.40×	–	–
Returns
Return on equity	19.3%	21.9%	21.2%	23.6%	22.5%	14.8%	22.6%	6.9%	14.2%	10.9%	9.6%	10.4%	13.9%	22.3%	23.5%	21.2%	(1.2%)	27.1%	19.7%	90.7%	3.5%	10.3%	(72.9%)	(22.3%)	3.0%	14.4%	15.1%	8.5%
Return on invested capital	16.2%	15.5%	17.9%	19.2%	18.1%	12.5%	16.3%	7.3%	16.5%	13.5%	12.5%	8.8%	5.6%	21.5%	35.3%	13.1%	–	20.5%	15.8%	13.7%	3.8%	14.0%	(30.4%)	(27.0%)	(14.7%)	13.9%	8.2%	9.5%
Dividend yield	0.7%	0.7%	0.9%	0.6%	0.5%	0.7%	0.9%	1.0%	0.8%	1.1%	1.2%	1.3%	1.3%	1.2%	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Financial health
Current ratio	1.96×	2.09×	2.61×	2.03×	2.22×	2.33×	1.53×	3.29×	3.30×	3.85×	3.78×	3.26×	3.11×	2.45×	3.03×	2.00×	3.53×	2.39×	2.21×	2.57×	2.30×	2.63×	2.04×	2.24×	2.40×	1.93×	2.10×	1.92×
Debt / equity	0.50×	0.57×	0.47×	0.52×	0.51×	0.48×	0.51×	0.39×	0.42×	0.45×	0.40×	0.31×	0.51×	0.46×	0.51×	1.14×	1.16×	0.59×	0.65×	0.41×	–	0.32×	0.41×	0.25×	0.00×	0.02×	–	–
Effective tax rate	9.2%	15.3%	7.4%	16.6%	11.0%	14.6%	(16.5%)	66.6%	14.8%	15.1%	8.8%	(1.3%)	23.2%	(10.5%)	1.9%	1.2%	542.9%	15.0%	4.8%	14.5%	61.0%	13.0%	(156.6%)	33.9%	14.9%	34.0%	33.9%	35.1%
Share count
Diluted shares outstanding	285	291	296	300	307	312	318	325	326	329	335	338	345	353	355	353	346	371	406	441	500	490	473	465	458	455	458	459

StatisticsIncome statementBalance sheetCash flowDividendsSegments

Income statement · USD millions

Line item	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008	FY2007	FY2006	FY2005	FY2004	FY2003	FY2002	FY2001	FY2000	FY1999	FY1998
Revenue and gross profit
Revenue	$7,372	$6,948	$6,510	$6,833	$6,848	$6,319	$5,339	$5,163	$4,914	$4,472	$4,202	$4,038	$4,048	$3,894	$6,858	$6,615	$5,444	$4,481	$5,774	$5,420	$4,973	$5,139	$7,181	$4,468	$6,010	$8,396	$9,361	$6,830	$7,952
Cost of revenue	($3,404)	($3,305)	($2,975)	($3,368)	($3,126)	($2,912)	($2,502)	($2,358)	($2,234)	($2,063)	($2,005)	($1,997)	($2,072)	($1,987)	($3,254)	($3,086)	($2,514)	($2,189)	($2,578)	($2,451)	($2,315)	($2,617)	($4,058)	–	($3,694)	($5,166)	($4,586)	($3,627)	($4,035)
Gross profit	$3,968	$3,643	$3,535	$3,465	$3,722	$3,407	$2,837	$2,805	$2,680	$2,409	$2,197	$2,041	$1,976	$1,907	$3,604	$3,529	$2,930	$2,292	$3,196	$2,969	$2,658	$2,522	$3,123	–	$2,316	$3,230	$4,775	$3,203	$3,917
Operating expenses
Research and development	($485)	($455)	($479)	($481)	($467)	($441)	($495)	($404)	($387)	($341)	($329)	($330)	($358)	($337)	($668)	($649)	($612)	($642)	($704)	($685)	($655)	($738)	($933)	($1,051)	($1,169)	($1,349)	($1,258)	($997)	($948)
Selling, general and administrative	($1,844)	($1,709)	($1,568)	($1,634)	($1,637)	($1,619)	($1,496)	($1,460)	($1,389)	($1,251)	($1,253)	($1,189)	($1,199)	($1,184)	($1,817)	($1,809)	($1,752)	($1,603)	($1,697)	($1,700)	($1,660)	($1,603)	($1,804)	($1,968)	($2,754)	($2,659)	($2,940)	($2,205)	($2,050)
Total operating expenses	($2,329)	($2,164)	($2,047)	($2,115)	($2,104)	($2,060)	($1,991)	($1,864)	($1,776)	($1,602)	($1,582)	($1,519)	($1,557)	($1,521)	($2,485)	($2,458)	($2,364)	($2,245)	($2,401)	($2,385)	($2,194)	($2,341)	($2,737)	–	($3,923)	($4,008)	($3,851)	($2,781)	($3,475)
Total costs and expenses	($5,733)	($5,469)	($5,022)	($5,483)	($5,230)	($4,972)	($4,493)	($4,222)	($4,010)	($3,665)	($3,587)	($3,516)	($3,629)	($3,508)	($5,739)	($5,544)	($4,878)	($4,434)	($4,979)	($4,836)	($4,509)	($4,958)	($6,795)	($5,188)	($7,617)	($9,174)	($8,437)	($6,408)	($7,510)
Operating income	$1,639	$1,479	$1,488	$1,350	$1,618	$1,347	$846	$941	$904	$807	$615	$522	$419	$386	$1,119	$1,071	$566	$47	$795	$584	$464	$181	$386	($720)	($1,607)	($778)	$924	$422	$442
Earnings
EBITDA	$1,910	$1,767	$1,745	$1,621	$1,935	$1,668	$1,154	$1,179	$1,114	$1,019	$861	$775	$803	$758	$1,420	$1,324	$768	$209	$996	$775	$634	$361	$598	($358)	($872)	($44)	$1,384	$862	$919
Interest income	$60	$62	$80	$51	$9	$2	$8	$36	$38	$22	$11	$7	$9	$7	$9	$14	$20	$29	$113	$172	–	–	–	–	–	–	–	–	–
Interest expense	($106)	($112)	($96)	($95)	($84)	($81)	($78)	($74)	($75)	($79)	($72)	($66)	($110)	($107)	($101)	($86)	($96)	($88)	($123)	($91)	–	–	–	($198)	–	–	–	–	($46)
Pre-tax income	$1,658	$1,435	$1,521	$1,339	$1,504	$1,360	$842	$919	$946	$803	$544	$480	$229	$293	$1,043	$1,032	$692	$7	$815	$670	$627	$254	$440	($696)	($1,547)	($477)	$1,018	$463	$396
Income tax expense	($218)	($132)	($232)	($99)	($250)	($150)	($123)	$152	($630)	($119)	($82)	($42)	$3	($68)	$110	($20)	($8)	($38)	($122)	($32)	($91)	($155)	($57)	($1,090)	$525	$71	($346)	($157)	($139)
Net income	$1,440	$1,303	$1,289	$1,240	$1,254	$1,210	$719	$1,071	$316	$684	$462	$401	$549	$734	$1,153	$1,012	$684	($31)	$693	$638	$3,307	$141	$369	($2,058)	($1,032)	$168	$757	$512	$257
Per share
Diluted EPS (GAAP)	$5.08	$4.57	$4.43	$4.19	$4.18	$3.94	$2.30	$3.37	$0.97	$2.10	$1.40	$1.20	$1.62	$2.13	$3.27	$2.85	$1.94	($0.09)	$1.87	$1.57	$7.50	$0.65	$0.75	($4.35)	($2.22)	$0.38	$1.66	$1.35	$0.56
Basic EPS (GAAP)	$5.09	$4.59	$4.44	$4.22	$4.19	$3.98	$2.33	$3.41	$0.98	$2.12	$1.42	$1.20	$1.65	$2.15	$3.31	$2.92	$1.97	($0.09)	$1.91	$1.62	$7.67	$0.66	$0.76	($4.35)	($2.22)	$0.38	$1.68	$1.35	$0.58
Basic shares outstanding	282	284	290	294	299	304	309	314	321	322	326	333	333	341	348	347	347	346	363	394	431	494	483	473	465	458	449	380	443
Margins
Gross margin	53.8%	52.4%	54.3%	50.7%	54.4%	53.9%	53.1%	54.3%	54.5%	53.9%	52.3%	50.5%	48.8%	49.0%	52.6%	53.3%	53.8%	51.1%	55.4%	54.8%	53.4%	49.1%	43.5%	–	38.5%	38.5%	51.0%	46.9%	49.3%
Operating margin	22.2%	21.3%	22.9%	19.8%	23.6%	21.3%	15.8%	18.2%	18.4%	18.0%	14.6%	12.9%	10.4%	9.9%	16.3%	16.2%	10.4%	1.0%	13.8%	10.8%	9.3%	3.5%	5.4%	(16.1%)	(26.7%)	(9.3%)	9.9%	6.2%	5.6%
Net margin	19.5%	18.8%	19.8%	18.1%	18.3%	19.1%	13.5%	20.7%	6.4%	15.3%	11.0%	9.9%	13.6%	18.8%	16.8%	15.3%	12.6%	(0.7%)	12.0%	11.8%	66.5%	2.7%	5.1%	(46.1%)	(17.2%)	2.0%	8.1%	7.5%	3.2%

Analyst consensus

Buy41 analysts

Bearish · 1 · Hold · 7 · Bullish · 33

Earnings history

	EPS	Estimate
Q4 2024	$1.46	$1.41	Beat
Q1 2025	$1.31	$1.28	Beat
Q2 2025	$1.31	$1.26	Beat
Q3 2025	$1.37	$1.37	Match
Q4 2025	$1.59	$1.58	Beat
Q1 2026	$1.36	$1.37	Miss
Q2 2026	$1.49	$1.41	Beat
Q3 2026	$1.62	$1.49	Beat

Peers

Company overview

IPO dateNov 18, 1999

CEOPadraig McDonnell

Employees18,200

SectorHealthcare

IndustryMedical - Diagnostics & Research

CountryUS

ExchangeNew York Stock Exchange

Websitewww.agilent.com

Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.